Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Revlimid

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Revlimid was produced by Celgene.

Celgene reaches $9bn agreement to buy Juno

Celgene reaches $9bn agreement to buy Juno Celgene is already a big player in blood cancers and haematology with Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide), and buying Juno keeps it in the running for a new generation ... of cell-based therapies in these areas at

Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

Unsure on efficacy, NICE passes J&J’s Darzalex to CDF Last year, NICE said it was unable to make a recommendation about use of Darzalex in combination with Celgene’s Revlimid (lenalidomide) and dexamethasone for relapsed and refractory myeloma because Janssen

Is acquisitive Celgene now eyeing CAR-T specialist Juno?

Is acquisitive Celgene now eyeing CAR-T specialist Juno? Buying Juno could make a lot of sense for Celgene, which is already a big player in blood cancers and could potentially pair its drug-based therapies such as blockbuster Revlimid

Progression-free Living

This, combined with loss of CDF funding for REVLIMID (lenalidomide) as a second line treatment posed a significant challenge to maintaining market share. ... REVLIMID can provide this. To address these challenges, Celgene fundamentally overhauled its data

Celgene gains French reimbursement for Revlimid in multiple myeloma

Celgene gains French reimbursement for Revlimid in multiple myeloma Celgene said Revlimid would still offer an “additional therapeutic option” in for patients with relapsed or refractory MCL who are ineligible for intensive chemotherapy and/or transplant. ... But in patients with a high tumour burden, HAS’

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics